MX2022010620A - Profarmacos de esteroides neuroactivos. - Google Patents

Profarmacos de esteroides neuroactivos.

Info

Publication number
MX2022010620A
MX2022010620A MX2022010620A MX2022010620A MX2022010620A MX 2022010620 A MX2022010620 A MX 2022010620A MX 2022010620 A MX2022010620 A MX 2022010620A MX 2022010620 A MX2022010620 A MX 2022010620A MX 2022010620 A MX2022010620 A MX 2022010620A
Authority
MX
Mexico
Prior art keywords
prodrugs
salts
sub
compounds disclosed
neuroactive steroids
Prior art date
Application number
MX2022010620A
Other languages
English (en)
Spanish (es)
Inventor
Lianhong Xu
Original Assignee
Brii Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brii Biosciences Inc filed Critical Brii Biosciences Inc
Publication of MX2022010620A publication Critical patent/MX2022010620A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
MX2022010620A 2020-02-27 2021-03-01 Profarmacos de esteroides neuroactivos. MX2022010620A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982717P 2020-02-27 2020-02-27
PCT/US2021/020308 WO2021174205A1 (en) 2020-02-27 2021-03-01 Prodrugs of neuroactive steroids

Publications (1)

Publication Number Publication Date
MX2022010620A true MX2022010620A (es) 2022-11-30

Family

ID=77491637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010620A MX2022010620A (es) 2020-02-27 2021-03-01 Profarmacos de esteroides neuroactivos.

Country Status (12)

Country Link
US (1) US20230416298A1 (he)
EP (1) EP4110345A4 (he)
JP (1) JP2023514873A (he)
KR (1) KR20230037006A (he)
CN (1) CN115461055B (he)
AU (1) AU2021226902A1 (he)
BR (1) BR112022016947A2 (he)
CA (1) CA3172901A1 (he)
IL (1) IL295902A (he)
MX (1) MX2022010620A (he)
TW (1) TW202146027A (he)
WO (1) WO2021174205A1 (he)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112111WA (en) 2019-05-10 2021-11-29 Brii Biosciences Inc Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
WO2021142477A1 (en) * 2020-01-12 2021-07-15 Brii Biosciences, Inc. Neuroactive steroids and pharmaceutical composition containing the same
CN114344309B (zh) * 2021-12-30 2024-02-06 南京迈诺威医药科技有限公司 一种别孕烷醇酮衍生物自乳化制剂及其制备方法
IL315509A (he) * 2022-03-18 2024-11-01 Marinus Pharmaceuticals Inc מטרימי תרופות של גנקסולון
CN119816292A (zh) * 2022-08-08 2025-04-11 先进核糖核酸疫苗(Arv)技术股份有限公司 基于甾醇的可电离脂质以及包含其的脂质纳米颗粒

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
KR100338287B1 (ko) * 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
FI972202L (fi) * 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2011120044A1 (en) * 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
CZ303443B6 (cs) * 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
FR2973031B1 (fr) * 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
CN119192266A (zh) * 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20170022245A1 (en) * 2013-11-26 2017-01-26 Biopharma Works Ganaxolone derivatives for treatment of central nervous systems disorders
US10137137B2 (en) * 2013-12-23 2018-11-27 Socpra Sciences Et Genie S.E.C. ATP synthase inhibitors and steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
US20190337975A1 (en) * 2018-05-04 2019-11-07 Acerus Pharmaceuticals Corporation Neurosteroid derivatives and uses thereof
CN108517001A (zh) * 2018-05-17 2018-09-11 江苏恩华络康药物研发有限公司 水溶性别孕烯醇酮衍生物及其用途
US20210300962A1 (en) * 2018-08-02 2021-09-30 Puretech Lyt, Inc. Lipid prodrugs of pregnane neurosteroids and uses thereof
SG11202112111WA (en) * 2019-05-10 2021-11-29 Brii Biosciences Inc Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
CR20240234A (es) * 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
CN115348864A (zh) * 2020-02-05 2022-11-15 纯技术Lyt股份有限公司 神经甾体的脂质前药
KR102885834B1 (ko) * 2020-04-10 2025-11-12 주식회사 엘지에너지솔루션 전지 모듈 및 이를 포함하는 전지 팩

Also Published As

Publication number Publication date
IL295902A (he) 2022-10-01
CN115461055B (zh) 2025-01-28
US20230416298A1 (en) 2023-12-28
BR112022016947A2 (pt) 2022-10-25
JP2023514873A (ja) 2023-04-11
WO2021174205A1 (en) 2021-09-02
EP4110345A1 (en) 2023-01-04
CA3172901A1 (en) 2021-09-02
CN115461055A (zh) 2022-12-09
KR20230037006A (ko) 2023-03-15
EP4110345A4 (en) 2024-05-15
AU2021226902A1 (en) 2022-09-22
TW202146027A (zh) 2021-12-16

Similar Documents

Publication Publication Date Title
MX2022010620A (es) Profarmacos de esteroides neuroactivos.
MX2022015419A (es) Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2).
ZA202307575B (en) Methods and modified nucleosides for treating coronavirus infections
MX2025011432A (es) Profarmacos antivirales y formulaciones de los mismos
MX2020002652A (es) Esteroides neuroactivos y su método de uso.
MX356702B (es) Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
WO2021202928A8 (en) Pharmaceutical compositions of niclosamide
EP4302764A3 (en) C17, c20, and c21 substituted neuroactive steroids and their methods of use
MY203159A (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
CO6270360A2 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
IL188172A0 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
BR112021018335A2 (pt) Derivados de benzodiazepina como inibidores de rsv
IL315023A (he) סטרואידים נוירואקטיביים לטיפול בהפרעות הקשורות למערכת העצבים המרכזית
CA3200722A1 (en) Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications
EP4464378A3 (en) Leucine, acetyl leucine, and related analogs for treating disease
BR112022007489A2 (pt) Forma amorfa de um receptor c5a de componente do complemento
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2025000635A (es) Compuestos cíclicos y métodos de utilización de estos
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
PH12022550512A1 (en) Liquid compositions comprising a levodopa amino acid conjugate and uses thereof
MX2023010450A (es) Composiciones liquidas estabilizadas que comprenden un conjugado de tirosina y levodopa, y usos de estas.
MX2018011142A (es) Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.